Development of Graves' Disease Following a Radioiodine Dose for the Shrinkage of a Multinodular Goiter After Using a Novel Protocol

作者：Pitoia Fabian^*; Chervin Raul; Nunez Selva; Salvai Maria E; El Tamer Elias; Schere Daniel; Niepomniszcze Hugo

来源：Endocrinologist, 2010, 20(1): 7-9.

DOI：10.1097/TEN.0b013e3181c9fe34

• multinodular
• goiter
• thyroid
• radioiodine
• TSH
• rhTSH

Objective: Following radioiodine (RI) therapy for multinodular goiter (MNG), 4% to 5% of patients are reported to develop Graves' hyperthyroidism. To show a new protocol for the administration of RI in MNG and to illustrate an infrequent adverse event observed after the RI dose.
Methods: A 70-year-old euthyroid woman with a tracheal compression and displacement. Baseline serum thyroid-stimulating hormone (TSH) was 1.1 mUI/mL, and RI uptake was 10% at 24 hours. The patient refused surgical treatment. We decided to employ a special protocol for increasing the thyroid uptake of (131)I. Methyl mercaptoimidazol (MMI) was administered orally (30 mg/d) to increase TSH levels. Thyroid hormones were measured monthly. Three months after initiation of MMI treatment, TSH levels increased to 5.3 mUI/mL, and thyroid RI uptake increased to 57% at 24 hours with more uniform uptake. She received an RI dose of 30 mCI(131)I. Six weeks later, she was euthyroid. Six months later, a CT showed a decrease in the thyroid size, but she was overtly hyperthyroid (TSH < 0.05 mUI/mL, T3 = 442 ng/dL, T(4) = 4.8 mu g/mL, and TSH receptor antibodies, TRAb > 55% [NV < 10%]).
Conclusion: We present this case to describe an infrequent adverse complication of RI administration in patients with NING. We also illustrate an alternative protocol for the administration of RI dose in such patients.

• 出版日期2010-2